Igrels - instructions for use, doses, side effects, contraindications

Igrele® is a sulfur-containing amino acid that forms in the body during the conversion of cysteine. Stimulates the processes of repair and regeneration in diseases of a dystrophic nature and diseases accompanied by a sharp disruption of the metabolism of the eye tissues.

It promotes the normalization of the functions of cell membranes, the activation of energy and metabolic processes, the preservation of the electrolyte composition of the cytoplasm due to the accumulation of K⁺ and Ca²⁺, improving the conditions for carrying out a nerve impulse.

Pharmacokinetics:With topical application, systemic absorption is low.

Indications:

-Dystrophy of the cornea;

- Old, traumatic, radiation and other types of cataracts;

- Injuries to the cornea (as a stimulant of reparative processes);

- Primary open-angle glaucoma in combination with β-adrenoblockers (to improve the outflow of watery moisture).

For all indications, the drug is used as part of complex therapy.

Contraindications:

Individual hypersensitivity to taurine, children under 18 years of age. Application in pregnancy and during breastfeeding

Sufficient experience in the use of the drug during pregnancy, breast-feeding is not.

Pregnancy and lactation:Possible application Igrele® for the treatment of pregnant and lactating mothers as prescribed by the attending physician if the expected benefit to the mother exceeds the potential risk to the fetus or child.

Dosing and Administration:

With cataracts a drug Assign in the form of instillations 1-2 drops 2-4 times a day for three months. The course is repeated at a monthly interval.

When traumas and dystrophic diseases cornea apply in the same doses within one month.

When open-angle glaucoma (In conjunction with butilaminogidroksipropoksifenoksimetil metiloksadiazolom and its combined form or timolol) - 1-2 drops 2 times a day, 15-20 min before the appointment of one of the antihypertensive drugs, for 6 weeks, followed by cancellation for 2 weeks.

Side effects:

Allergic reactions.

If the side effects listed in the manual are aggravated,or you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

Data on overdose are absent.

Interaction:

In patients with glaucoma (open-ended), a significant increase in the antihypertensive effect of β-adrenoblockers (timolol and butylamine hydroxypropoxyphenoxy imethyl methyloxadiazole) in the case of joint use with Igrele®.

Strengthening the effect is achieved by increasing the coefficient of ease of outflow and reducing the production of aqueous humor.

Special instructions:

Form release / dosage:

Eye drops 4%.

Packaging:1.5 ml, 2 ml or 5 ml in a tube-dropper polymer.

1, 2, 4, 5 or 10 tubes with instructions for use and instructions for use in a pack of cardboard with partitions or without partitions.

5 ml or 10 ml into the bottle-dropper polymer.

1 or 2 vials of a dropper with instructions for the use of the drug in a pack of cardboard.

The text of the instruction for the use of a tube-dropper or a bottle-dropper is applied on the packet.

5 ml into glass bottles.

1 bottle complete with a lid-dropper in a sterile version and instructions for the use of the drug in a pack of cardboard.

5 bottles in a planar cell packaging made of a polyvinyl chloride film.

1 a contoured cellular package complete with 5 dropper caps in a sterile version and instructions for the use of the drug in a pack of cardboard.

Storage conditions:

In the dark place at a temperature of no higher than 15 ° C.

Keep out of the reach of children.

Shelf life:2 year in a tube-droppers and in a vial or flask-droppers. 4 years in vials.

After autopsy - 1 month.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:LP-001368

Date of registration:19.12.2011 / 15.02.2017

Expiration Date:Unlimited

The owner of the registration certificate:KVADRAT-S, LLCKVADRAT-S, LLC Russia

Manufacturer: & nbsp

MOSCOW ENDOCRINE FACTORY, FSUE Russia

Information update date: & nbsp22.10.2017

Illustrated instructions

Instructions

Igrele® (Igrele®)